药品注册申请号:022562
申请类型:NDA (新药申请)
申请人:RECORDATI RARE
申请人全名:RECORDATI RARE DISEASES INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 CARBAGLU CARGLUMIC ACID TABLET, FOR SUSPENSION;ORAL 200MG Yes Yes AB 2010/03/18 2010/03/18 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/01/19 SUPPL-14(补充) Approval Labeling STANDARD ;Orphan
2021/08/05 SUPPL-13(补充) Approval Labeling STANDARD ;Orphan
2021/01/22 SUPPL-9(补充) Approval Efficacy PRIORITY ;Orphan
2021/01/22 SUPPL-8(补充) Approval Efficacy PRIORITY ;Orphan
2020/08/26 SUPPL-12(补充) Approval Labeling STANDARD ;Orphan
2019/12/23 SUPPL-11(补充) Approval Labeling STANDARD ;Orphan
2017/11/16 SUPPL-5(补充) Approval Labeling STANDARD ;Orphan
2015/11/05 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
2014/01/23 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
2013/08/05 SUPPL-2(补充) Approval Labeling STANDARD
2013/07/22 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY ;Orphan
2010/03/18 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY ;Orphan
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 ODE-345 2028/01/22
001 NCE 2015/03/18**本条是由Drugfuture回溯的历史信息**
ODE 2017/03/18**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:CARGLUMIC ACID 剂型/给药途径:TABLET, FOR SUSPENSION;ORAL 规格:200MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022562 001 NDA CARBAGLU CARGLUMIC ACID TABLET, FOR SUSPENSION;ORAL 200MG Prescription Yes Yes AB 2010/03/18 RECORDATI RARE
213729 001 ANDA CARGLUMIC ACID CARGLUMIC ACID TABLET, FOR SUSPENSION;ORAL 200MG Prescription No No AB 2021/10/13 NOVITIUM PHARMA
213395 001 ANDA CARGLUMIC ACID CARGLUMIC ACID TABLET, FOR SUSPENSION;ORAL 200MG Prescription No No AB 2022/06/22 NAVINTA LLC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database